HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics

@inproceedings{Laino2019HDAC6SI,
  title={HDAC6 selective inhibition of melanoma patient T-cells augments anti-tumor characteristics},
  author={Andressa Sodre Laino and B Betts and Anandharaman Veerapathran and Igor Dolgalev and Amit P. Sarnaik and Steven Norman Quayle and S. Shephard Jones and Jeffrey S. Weber and David Michael Woods},
  booktitle={Journal for ImmunoTherapy of Cancer},
  year={2019}
}
BackgroundTherapies targeting anti-tumor T-cell responses have proven successful in the treatment of a variety of malignancies. However, as most patients still fail to respond, approaches to augment immunotherapeutic efficacy are needed. Here, we investigated the ability of histone deacetylase 6 (HDAC6)-selective inhibitors to decrease immunosuppression and enhance immune function of melanoma patient T-cells in ex vivo cultures.MethodsT-cells were harvested from peripheral blood or tumor… CONTINUE READING
4
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 50 REFERENCES

FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression.

  • Proceedings of the National Academy of Sciences of the United States of America
  • 2007
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL